Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 64 of 668 for:    CARBON DIOXIDE AND arterial

High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV) (HINPPV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01214200
Recruitment Status : Completed
First Posted : October 4, 2010
Results First Posted : January 1, 2019
Last Update Posted : January 1, 2019
Sponsor:
Information provided by (Responsible Party):
Philips Respironics

Brief Summary:
The purpose of this pilot study is to evaluate the effect of high intensity non-invasive positive pressure ventilation (HINPPV) for stable, hypercapnic COPD patients. The investigators believe that HINPPV, used at least 6 hours nocturnally over three months, will benefit the stable hypercapnic COPD patient through a reduction in the daytime partial pressure of carbon dioxide in arterial blood (PaCO2) levels.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease (COPD) Device: Bilevel positive airway pressure (BiPAP) Not Applicable

Detailed Description:
The High Intensity Non-invasive Positive Pressure trial is a single arm interventional study. The purpose of this study is to evaluate the effect of High Intensity Non-invasive ventilation (HINPPV) in stable Chronic Obstructive Pulmonary patients with chronically elevated carbon dioxide levels. Participants will undergo various testing ( arterial blood gas (ABG), Pulmonary Function Test (PFTs), Polysomnography (PSGs), 6 minute walk tests)over a 3 month period to determine if this type of therapy will improve daytime carbon dioxide levels. The participants will also complete quality of life questionnaires to help ascertain improvements in their daily living activities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV) for Stable Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Patients
Study Start Date : August 2010
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Arm Intervention/treatment
Experimental: High Intensity Non Invasive Pos.Pressure
The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
Device: Bilevel positive airway pressure (BiPAP)
This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
Other Name: Synchrony BiPAP ventilator and Trilogy Ventilator




Primary Outcome Measures :
  1. Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2) [ Time Frame: Before and after 3 months of therapy ]
    Daytime PaCO2 levels assessed after using high intensity non-invasive positive pressure ventilation (HINPPV) are compared to the participants' baseline daytime PaCO2 levels.


Secondary Outcome Measures :
  1. Health Status [ Time Frame: Before and after 3 months of therapy ]
    Health status was assessed by completing different surveys at baseline and after 3 months of therapy. The Calgary Sleep Apnea Quality of Life was administered at baseline and 3 months. It is a 35-item, interview-administered scale, the SAQLI evaluates four domains of quality of life associated with sleep apnea: daily functioning, social interactions, emotional functioning, and symptoms. The SAQLI use a 7-point Likert scale ranging from 1 (maximal impairment) to 7 (no impairment).

  2. Maximal Inspiratory Pressure [ Time Frame: Before and after 3 months of therapy ]
    The Maximal inspiratory pressure (MIP) is the maximum negative pressure that can be generated from one inspiratory effort starting from functional residual capacity (FRC) or residual volume (RV). This was assessed at baseline and after 3 months of therapy.

  3. Exercise Capacity [ Time Frame: Before and after 3 months of therapy ]
    Exercise capacity will be measured by comparing the 6 minute walk test as measured in meters from baseline to 3 months

  4. Dyspnea at Rest and With Exertion [ Time Frame: Before and after 3 months of therapy ]
    The modifed Borg scale was used to measure dyspnea. The Dyspnea Borg scale measures patients perceived level of dyspnea. The scale ranges from 0 to 10, 0- nothing at all and 10 is maximal.

  5. Sleepiness [ Time Frame: Before and after 3 months of therapy ]
    Sleepiness will be evaluated by measuring the the baseline and 3 month Epworth Sleepiness Scale. The Epworth Sleepiness Scale is an 8 question survey regarding daytime sleepiness. The higher the score the higher the chance of dozing during the day. Each question is rated on a 0 to 3 scale of chance of dozing or sleeping. 0 would be no chance, 3 would be the highest chance.

  6. Duration of Sleep [ Time Frame: Before and after 3 months of therapy ]
    Duration of sleep will be measured using total sleep time. Total sleep time is the overall number of minutes of sleep, this will be compared from baseline to 3 months.

  7. Efficiency of Sleep [ Time Frame: Before and after 3 months of therapy ]
    Sleep efficiency will be measured by taking the total sleep time by the total time in bed. This is measured as a percentage and compared from baseline to 3 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Patient diagnosed with chronic obstructive pulmonary disease (COPD)
  2. Age < or = to 80 years
  3. Forced expiratory volume in one second (FEV1) < 50% of predicted value
  4. FEV1/Forced vital capacity (FVC) < 70% of predicted value
  5. Total lung capacity (TLC) > 90% predicted by plethysmography
  6. Body Mass Index (BMI) < 35
  7. Patient has provided written informed consent using a form that has been approved by the Internal Review Board (IRB)
  8. Daytime PaCO2 ≥ 52 mm Hg, at rest on room air (Denver > 48 mm Hg) with one of the following symptoms of hypercapnia:

    • Fatigue
    • Sleepiness
    • Headaches
  9. Post hospital discharge at least one month prior to screening visit
  10. Participant is willing and able to complete all required assessments and procedures
  11. Participant has no child bearing potential OR a negative pregnancy test in a woman of childbearing potential

Exclusion Criteria

  1. FEV1 < 15% of predicted value
  2. Diagnosis of obstructive sleep apnea (OSA) [Apnea hypopnea index (AHI) > 15 per hour]
  3. Current Non-invasive Positive Pressure Ventilation (NIPPV), Positive Airway Pressure (PAP) or Non-invasive Ventilation (NIV) users
  4. Signs / symptoms of acute exacerbation within the previous month: two of the following criteria:

    • Increasing cough
    • Purulent sputum
    • Current use of antibiotics
    • pH < 7.35
  5. Any major non COPD disease or condition that interferes with completion of initial or follow-up assessments, such as uncontrolled malignancy, end-stage heart disease, liver or renal insufficiency (that requires current evaluation for liver or renal transplantation or dialysis), amyotrophic lateral sclerosis, or severe stroke, or other as deemed appropriate by investigator as determined by review of medical history and / or patient reported medical history
  6. History of pneumothorax
  7. Anatomical facial abnormalities precluding placement of a nasal or facial mask
  8. Diffuse parenchymal lung disease other than emphysema
  9. Inability to maintain Oxygen (O2) saturation >90% on 5L/min ( five liters) nasal O2 at rest
  10. Sustained need for >10 mg prednisone daily or equivalent dose of other systemic corticosteroid
  11. Pregnancy
  12. Excessive alcohol intake (≥ 6oz hard liquor daily), or illicit drug use
  13. Daily use of narcotics (greater than 30 mg morphine equivalent)
  14. Patient is currently enrolled in another interventional clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01214200


Locations
Layout table for location information
United States, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania, United States, 19140
Sponsors and Collaborators
Philips Respironics
Investigators
Layout table for investigator information
Principal Investigator: Gerald Criner, MD Temple Medical Center

Layout table for additonal information
Responsible Party: Philips Respironics
ClinicalTrials.gov Identifier: NCT01214200     History of Changes
Other Study ID Numbers: HRC-0927-HINPPV-MS
First Posted: October 4, 2010    Key Record Dates
Results First Posted: January 1, 2019
Last Update Posted: January 1, 2019
Last Verified: December 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases